Traditional MedicareCoverageMedium impact
MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma
Medicare/CMS - LCD·Dermatology, Oncology, Pathology·Local Coverage Determination
Effective date
May 28, 2026
We identified it
Jun 17, 2026
Summary
Medicare has established a new Local Coverage Determination for molecular biomarker testing to assess risk levels in cutaneous squamous cell carcinoma patients. This policy will define coverage criteria and billing requirements for specialized genetic testing used to determine cancer progression risk and guide treatment decisions.
Action Required
Before May 28, 2026: Billing team must review the full LCD policy text to understand coverage criteria for molecular biomarker testing in cutaneous squamous cell carcinoma cases. Update billing procedures to ensure proper documentation and medical necessity requirements are met for these specialized tests. Coordinate with dermatology and oncology providers to establish compliant ordering and billing workflows.